Correspondence | Published:

Chemotherapy vs. allogeneic transplantation as post molecular remission therapy in patients aged less than 60 years with Philadelphia-positive ALL

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644–52. https://doi.org/10.1200/JCO.2010.28.1287

  2. 2.

    Chiaretti S, Vitale A, Vignetti M, Piciocchi A, Fazi P, Elia L, et al. A sequential approach with imatinib, chemotherapy and transplant for adult Ph+acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101:1544–52. https://doi.org/10.3324/haematol.2016.144535

  3. 3.

    Slayton WB, Schultz KR, Kairalla JA, Devidas M, Mi X, Pulsipher MA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults With Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s Oncology Group Trial AALL0622. J Clin Oncol. 2018;36:2306–14. https://doi.org/10.1200/JCO.2017.76.7228

  4. 4.

    Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grumayer R, Peters C, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia. 2015;29:1648–55. https://doi.org/10.1038/leu.2015.59

  5. 5.

    Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51:43–50. https://doi.org/10.1038/bmt.2015.217

  6. 6.

    Pemmaraju N, Kantarjian H, Jorgensen JL, Jabbour E, Jain N, Thomas D, et al. Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. Am J Hematol. 2017;92:279–85. https://doi.org/10.1002/ajh.24629

  7. 7.

    Short NJ, Jabbour E, Sasaki K, Patel K, O’Brien SM, Cortes JE, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504–7. https://doi.org/10.1182/blood-2016-03-707562

  8. 8.

    Cai WZ, Cen JN, Chen J, Chen F, Fu CC, Han Y, et al. Major molecular response prior to allogeneic hematopoietic stem cell transplantation predicts better outcome in adult Philadelphia-positive acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 2017;52:470–2. https://doi.org/10.1038/bmt.2016.307

  9. 9.

    Zhang WP, Yang D, Song XM, Ni X, Chen J, Chen L, et al. Allogeneic peripheral blood stem cell transplantation is a promising and safe choice for the treatment of refractory/relapsed acute myelogenous leukemia, even with a higher leukemia burden. Biol Blood Marrow Transplant. 2013;19:653–60. https://doi.org/10.1016/j.bbmt.2013.01.015

  10. 10.

    Zhang WP, Wang ZW, Hu XX, Chen J, Yang D, Song XM et al. Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study. Bone Marrow Transplant. 2018. https://doi.org/10.1038/s41409-018-0356-5

  11. 11.

    Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22:1983–7. https://doi.org/10.1016/j.bbmt.2016.07.021

  12. 12.

    Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, et al. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016;27:1081–8. https://doi.org/10.1093/annonc/mdw123

  13. 13.

    Ravandi F, Jorgensen JL, Thomas DA, O’Brien S, Garris R, Faderl S, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–21. https://doi.org/10.1182/blood-2012-11-466482

  14. 14.

    Schultz KR, Carroll A, Heerema NA, Bowman WP, Aledo A, Slayton WB, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28:1467–71. https://doi.org/10.1038/leu.2014.30

  15. 15.

    Ribera JM, Ribera J, Genescà E. The role of stem cell transplantation in the management of Philadelphia chromosome positive acute lymphoblastic leukemia. Ther Adv Hematol. 2018;9:357–68. https://doi.org/10.1177/2040620718811772

Download references

Acknowledgements

This work was supported by National Natural Science Foundation of China (NSFC; 81770160, 81470321, 81270567). XH was sponsored by Scholarship from Shanghai Municipal Health and Family Planning Commission (2017BR012).

Author information

Correspondence to Xiaoxia Hu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Table S1

Table S2

Figure S1

Figure S2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1